BC Extra | Mar 7, 2019
Company News

Moderna announces pipeline updates in first financial results

In its first quarterly financial results as a public company, Moderna announced its first rare disease mRNA program is heading to the clinic. Moderna Inc. (NASDAQ:MRNA) said Wednesday that it has submitted an IND for...
BC Innovations | Feb 1, 2019
Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
BC Week In Review | Jan 25, 2019
Clinical News

BMS pulls sBLA for Opdivo/Yervoy combo in first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said it has withdrawn an sBLA for anti-PD-1 mAb Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab for first-line treatment of lung cancer, citing a need for more evidence of the relationship...
BC Extra | Jan 24, 2019
Company News

BMS pulls sBLA for Opdivo/Yervoy combo in first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said it has voluntarily withdrawn its sBLA for anti-PD-1 mAb Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab for first-line treatment of lung cancer, citing a need for more evidence of the...
BC Week In Review | Oct 26, 2018
Clinical News

FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said on Oct. 19 that FDA and EMA have both pushed back their reviews of anti-PD-1 mAb Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab for first-line non-small cell lung cancer. The...
BC Week In Review | Oct 26, 2018
Financial News

LogicBio joins PhaseBio, Osmotica in missing IPO price target

LogicBio Therapeutics Inc. (NASDAQ:LOGC) priced its IPO below its proposed range late Oct. 18, joining two other biotechs that missed their target price the week of Oct. 15. But shares of the genome editing company...
BC Extra | Oct 19, 2018
Company News

FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said Friday that FDA and EMA have both pushed back their reviews of anti-PD-1 mAb Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab for first-line non-small cell lung cancer. The company also...
BC Extra | Oct 19, 2018
Financial News

LogicBio marks week’s third IPO to miss price target

LogicBio Therapeutics Inc. (NASDAQ:LOGC) priced its IPO below its proposed range late Thursday, joining two other biotechs that missed their target price this week. But shares of the genome editing company jumped $1.90 (19%) to...
BC Week In Review | Sep 28, 2018
Financial News

Gene therapy play LogicBio proposes IPO

Gene therapy company LogicBio Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $86 million in an IPO on NASDAQ underwritten by Jefferies, Barclays, William Blair and Chardan. LogicBio is developing gene therapies to address...
BC Extra | Sep 26, 2018
Financial News

Gene therapy play LogicBio proposes IPO

Gene therapy company LogicBio Therapeutics Inc. (Cambridge, Mass.) proposed to raise up to $86 million in an IPO on NASDAQ underwritten by Jefferies, Barclays, William Blair and Chardan. LogicBio is developing gene therapies to address...
Items per page:
1 - 10 of 24